Results from the CAR-PRISM phase 2 trial show that the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) produced remarkable outcomes in patients with high-risk smoldering multiple myeloma, a precursor to active cancer. All 20 patients in the study responded to treatment, with most achieving deep remissions. Every patient became minimal residual disease (MRD) negative within two […]
New research shows that combining comprehensive tumor profiling with blood-based DNA monitoring can guide treatment for most patients with breast and colorectal cancer. Using advanced genomic testing alongside circulating tumor DNA (ctDNA) analysis, researchers found that 98% of patients had at least one actionable genetic alteration, and over half had markers linked to approved targeted
The U.S. FDA has approved nivolumab (Opdivo) in combination with AVD chemotherapy for patients aged 12 and older with newly diagnosed advanced classical Hodgkin lymphoma. This approval expands access to a modern immunotherapy-based treatment for both adults and adolescents. Results from the SWOG 1826 trial showed the combination reduced the risk of disease progression or
A study examined relapse in patients with myelofibrosis and blast-phase myeloproliferative neoplasms after allogeneic stem cell transplant. Among 47 patients treated between 2013 and 2024, 21% experienced recurrence, with 3- and 5-year relapse rates both at 35%. Molecular relapse typically appeared about six months after transplant and was often detected by declining donor chimerism. Donor
Researchers are reporting major progress in targeting KRAS, a cancer-driving protein long considered “undruggable.” Mutations in KRAS keep cells stuck in a constant growth mode, contributing to some of the most aggressive cancers, including pancreatic cancer. Instead of simply trying to block KRAS activity, scientists are now developing “degrader” drugs that label the mutant protein
New KRAS-Targeting Strategies Bring Fresh Hope to Cancer Treatment Read More »
A phase 2 clinical trial of the experimental drug elraglusib has shown promising results for patients with metastatic pancreatic cancer, according to research published in Nature Medicine. Patients who received elraglusib along with chemotherapy were twice as likely to be alive after one year compared to those who received chemotherapy alone, with survival rates of
A new study has found a surprising link between healthy diets and a higher risk of lung cancer in non-smokers under age 50, especially women. Researchers reported that younger non-smokers diagnosed with lung cancer had better diet quality than average, scoring 65 on the Healthy Eating Index compared to the national average of 57. Women in
Healthy Diets Linked to Unexpected Rise in Lung Cancer Among Young Non-Smokers Read More »
A natural compound extracted from purple sweet potatoes may offer a new way to fight colorectal cancer, according to a recent study. The compound, called Cya-Gly-Fer (CGF), showed strong anti-tumor effects in both laboratory and animal models, significantly slowing tumor growth and reducing liver metastasis, a major cause of death in colorectal cancer patients. Researchers
Researchers have developed a new nanomedicine, SH-EM-NP/EPI, aimed at improving treatment for bladder cancer by addressing key limitations of current therapies. In non-muscle-invasive bladder cancer (NMIBC), which accounts for about 75% of cases, recurrence rates remain high—up to 70% within five years—largely because drugs are quickly flushed out of the bladder and struggle to penetrate
A new study has developed the PNI-HB score, a simple blood-based tool to predict outcomes in patients with relapsed or refractory non-Hodgkin lymphoma undergoing CD19 CAR T-cell therapy. Unlike the traditional International Prognostic Index (IPI), the new model focuses on nutritional status and hemoglobin levels, offering a more relevant approach in the immunotherapy era. In
New PNI-HB Score Improves Outcome Prediction in CAR T Therapy for Non-Hodgkin Lymphoma Read More »